Pulmonary Hemorrhage in Premature Infants: Pathophysiology, Risk Factors and Clinical Management

Area of Science:

• Neonatology
• Pediatric Pulmonology
• Critical Care Medicine

Background:

• Pulmonary hemorrhage (PH) is a severe complication in preterm infants, linked to very low birth weight and fetal growth restriction.
• It typically manifests within 72 hours of birth, causing rapid respiratory decline, significant illness, and mortality.
• The condition arises from complex factors including immature lung vasculature, hemodynamic changes from surfactant, and impaired left ventricular function.

Purpose of the Study:

• To review the multifactorial causes of pulmonary hemorrhage in preterm infants.
• To synthesize current knowledge on diagnostic methods and management strategies for PH.
• To identify areas for future research and improved clinical outcomes.

Main Methods:

• Literature review synthesizing current evidence on PH pathogenesis, risk factors, diagnosis, and management.
• Analysis of diagnostic tools including clinical assessment, imaging, lung ultrasound, and echocardiography.
• Evaluation of current and emerging therapeutic interventions, including ventilatory support, surfactant, blood products, and hemostatic agents.

Main Results:

• Key risk factors identified include respiratory distress syndrome (RDS), patent ductus arteriosus (hsPDA), sepsis, coagulopathies, and genetic factors.
• Effective management involves ventilatory support (HFOV), surfactant, blood transfusions, and hemostatic agents.
• Antenatal corticosteroids and early indomethacin may reduce PH incidence in high-risk infants.

Conclusions:

• Pulmonary hemorrhage remains a significant cause of mortality and neurodevelopmental issues in neonates despite advances in care.
• Further research is needed for individualized risk assessment, early diagnosis, and optimized treatment protocols.
• Multidisciplinary collaboration and innovation are crucial for improving care for infants with PH.